Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Subsidiary BioFocus Signs Agreement with Biogen Idec in Scleroderma

Published: Monday, November 18, 2013
Last Updated: Sunday, November 17, 2013
Bookmark and Share
Will leverage Galapagos' SilenceSelect® platform and unique human skin models.

Galapagos NV has announced that its subsidiary BioFocus has signed a 3-year collaboration agreement with Biogen Idec focused on the identification and validation of novel targets in scleroderma.

Galapagos' service division BioFocus will use its SilenceSelect® platform and unique human skin models to deliver new assays and identify disease-modifying targets in scleroderma to Biogen Idec.

Under the terms of the agreement, BioFocus will receive an upfront payment, FTE funding, and will be eligible to receive success payments for target discovery milestones to be delivered by BioFocus and development milestones achieved by Biogen Idec.

The total value of this collaboration to BioFocus could reach $31 million.

"We believe Galapagos has unique expertise with relevant human primary cells, positioning them well to find new targets for disease-modifying therapies against scleroderma," said Jo Viney, vice president of discovery sciences at Biogen Idec.

"We welcome Biogen Idec to our client base and look forward to applying our versatile target discovery engine to yet another new disease area with unmet medical need," added David Smith, CEO Galapagos Services.

Scleroderma is an autoimmune disease characterized by hardening of the skin. Patients with diffuse scleroderma also experience hardening of the organs, which can be particularly disabling and also fatal.

Scleroderma is found worldwide, affecting 1 in 1000 in the United States, with women four times more likely than men to develop the disease.

The root causes of the disease are not well understood, and there are no disease-modifying treatments.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos and MorphoSys initiate Phase 1 study
Company has initiated phase 1 study with MorphoSys AG in joint antibody program MOR106.
Friday, April 08, 2016
Galapagos Receives Grant from IWT
Company has been awarded €2.4 million TGO grant for psoriasis research and development.
Monday, July 08, 2013
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease.
Friday, May 17, 2013
Abbott and Galapagos Announce Global Collaboration
Selective JAK1 inhibitor in Phase II clinical development for rheumatoid arthritis.
Thursday, August 23, 2012
Galapagos Gives R&D Update
Competitive positioning and Phase II study plans in RA for GLPG0634.
Monday, April 23, 2012
Scientific News
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Go-Between Immune Cell is Key to Priming the Body’s Fight Against Cancer
‘Antigen-presenting cell’ activates T cells by alerting them to the presence of tumors.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!